250mg Geffy Gefitinib Tablets

250mg Geffy Gefitinib Tablets Specification

Life Span
24 months from the date of manufacture

Dosage Form
Tablet

Origin of Medicine
India

Brand Name
Geffy

Indication
Advanced or metastatic non-small cell lung cancer with EGFR mutations

Packaging Type
Blister Pack

Pacakaging (Quantity Per Box)
30 tablets

Salt Composition
Gefitinib 250mg

Drug Type
Prescription only

Ingredients
Gefitinib 250mg

Physical Form
Tablet

Function
Anti-cancer medication | EGFR inhibitor

Recommended For
Non-Small Cell Lung Cancer (NSCLC) patients

Dosage
As prescribed by the physician

Dosage Guidelines
Take orally once daily with or without food, or as directed by the doctor

Suitable For
Adults

Quantity
30 Tablets per box

Storage Instructions
Store in a cool, dry place below 30C. Protect from light and moisture.

ATC Code
L01XE02

Shape
Round

Precautions
Not for use in children; use caution in hepatic or renal impairment

Side Effects
Rash, diarrhea, dry skin, vomiting, nausea, interstitial lung disease (rare)

Route of Administration
Oral

Warning
Use only under medical supervision

Pregnancy Category
D (Positive evidence of risk)

Colour
White to off-white

Strength
250mg per tablet

Patient Advice
Continue treatment as prescribed; do not adjust dose without consulting your doctor

Shelf Life
2 years

250mg Geffy Gefitinib Tablets Trade Information

Minimum Order Quantity
10 Strips

Supply Ability
5000 Strips Per Month

Delivery Time
7 Days

About 250mg Geffy Gefitinib Tablets

Dose/Strength	250 mg
Form	Tablet
Brand	Geftib
Packaging Size	30 Tablets
Manufacturer	Glenmark Pharmaceuticals Ltd
Pack Type	Bottle
Treatment	Treats Non-Small Cell Lung Cancer

Gefitinib(Iressa) generic Geftib is a chemotherapy agent, prescribed for non-small cell lung cancer. It blocks the action of a certain substance that may be needed for cancer cell multiplication.

Precise Treatment for NSCLC Patients

Geffy 250mg is designed for individuals with advanced or metastatic non-small cell lung cancer (NSCLC) with documented EGFR mutations. By inhibiting epidermal growth factor receptors, the medicine specifically targets and slows down cancer cell proliferation, offering a focused therapeutic approach when prescribed and monitored by a healthcare professional.

Usage and Dosage Guidelines

Patients are typically directed to take one Geffy 250mg tablet orally each day, with or without food. It is imperative to adhere to your physician's instructions and not to change the dose on your own. Continuous therapy, as prescribed, maximizes potential benefits and helps manage the disease more effectively.

Safety and Patient Precautions

Geffy is not suitable for children and must be administered cautiously in those with liver or kidney impairment. The medication should only be used under strict medical supervision due to potential side effects such as rash, diarrhea, and rare lung complications. Pregnant women are advised against its use due to the risk category D rating.

FAQ's of 250mg Geffy Gefitinib Tablets:

Q: How should I take Geffy Gefitinib 250mg tablets?

A: Take one Geffy tablet orally once daily, as prescribed by your doctor, with or without food. Always follow your physician's dosage instructions and continue treatment as advised without making changes on your own.

Q: What is Geffy used for and who can take it?

A: Geffy Gefitinib is used for treating adults with advanced or metastatic non-small cell lung cancer (NSCLC) that has EGFR mutations. It is not suitable for children and is intended for adults under strict medical supervision.

Q: When should I inform my healthcare provider while using Geffy?

A: Notify your doctor immediately if you experience symptoms such as severe rash, persistent diarrhea, breathing difficulties, or any signs of allergic reaction. Also, discuss any existing hepatic or renal diseases before starting treatment.

Q: Where should I store Geffy tablets?

A: Keep Geffy tablets in their original blister packaging, stored in a cool, dry place below 30C. Protect the medication from light and moisture, and keep it out of reach of children.

Q: What precautions should I observe during Geffy treatment?

A: Do not use Geffy if you are pregnant or plan to become pregnant due to its Pregnancy Category D risk. Patients with liver or kidney issues should exercise caution and consult their doctor regularly. Never adjust your dose without medical advice.

Q: What benefits does Geffy offer for NSCLC patients?

A: Geffy specifically targets EGFR mutations in NSCLC, helping to slow cancer progression and improve disease management. Its oral formulation provides convenience, and regular dosage can effectively inhibit tumor growth under medical oversight.